We cannot guarantee that the content will display correctly while using Internet Explorer. To have the best browsing experience, please upgrade to Microsoft Edge, Google Chrome or Safari.

October 18, 2019

Measuring Digital Health Maturity: Review of Top 10 Pharma Activity Over the last 5 Years

Reports
HealthXL Research Team
&

Measuring Digital Health Maturity: Review of Top 10 Pharma Activity Over the last 5 Years 

Intrigued? 

It perhaps comes at an opportune time, with the Sandoz- Pear Therapeutics breakup announced this week, to assess how big pharma have been engaging with technologies in recent years, what this means for the health industry, and if money is following the patient. 


As pharmaceutical companies begin to explore the true value and potential of technology, it is difficult to ascertain to what extent these companies are actually engaging with digital to drive change to the status quo either by increasing revenue/ market share, diversifying their product portfolio, or speeding up drugs’ time to market. 


This quarter, we assessed the digital health maturity of the Top 10 pharmaceutical companies (by revenue) over the past 5 years in the following four areas -  investment, acquisition, partnerships, and hiring initiatives. 




Activity comparative 2014 - 2019


Digital Health Investments: from spray and pray to strategic 

It’s no secret that pharma have been increasingly investing in digital health solutions. According to our findings, since 2014, the top 10 pharma companies have contributed to 129 digital health investments and 8 acquisitions of digital health companies, accounting for over 13% of their shared investment activity during that period. While we identified investment activity in 8 of the 10 pharma companies, only 2 (Roche and Merck) have doubled down on their investments, and converted them into acquisitions in the digital health space.


While the total number of investments appear to be decreasing, the amount of capital being invested is increasing, with the exception of 2017 which was offset by the mammoth GRAIL investment of $1.2B. Is this a sign of investors knowing better what they're looking for instead of adopting a spray and pray approach? We think so. 


Number of investments and total investment amounts


Using Roche as an example (shown below), data from the HealthXL platform gives us an inkling as to what each organisation’s digital health investment and acquisition strategy may be. 

Roche exhibits a pattern of multiple repeat investments precluding an acquisition. We have seen this with the MySugr investment in 2015 and subsequent acquisition in 2017, again with the Flatiron investment in 2016 and subsequent acquisition in 2018 and finally with Viewics investment in 2016 and acquisition in 2017. Whether or not this tells us where the next Roche move will be remains unknown, however these emerging patterns across the 10 profiled pharma companies may provide a nod towards some of the internal investment and acquisitions taking place. 


Roche sample insight


Digital Health Partnerships: R&D is too time consuming and capital intensive

Our data revealed that partnerships are on a steady increase, with digital health related partnership activity increasing almost 3 fold since 2014. Among the top 10 pharma, Novartis have announced the most partnerships since 2014. Pfizer and Merck were the pioneers of early (2014) partnership activity, while Roche and Sanofi have become more active going into 2019. We investigated the types of digital health companies the top 10 pharma are partnering with and found that most companies pharma chose to partner with work in cardio-metabolic disease and specifically help in remotely monitoring patients through digital means.

Partnerships comparative


Partnerships were formed to either augment R&D capabilities, or support commercial arms of the business. We discovered that the top 10 pharma displayed a preference for commercial partnerships over research partnerships. In fact, commercial partnerships accounted for 73% of all digital health related partnership activity. Interestingly, Sanofi emerged as the only organisation to have more research partnerships than commercial, with all of their 2019 partnership activities having a research focus. We reckon big pharma are placing bets on commercial partnerships because they are faster to market. 


Research and commercial partnership timeline


So, what next? 

Data = Understanding. We’ve laid out the facts. For pharma, this report shows how you stack up in the digital journey against other pharmaceutical companies. For start-ups, it could tell you how to position yourself as attractive to large pharmaceutical companies. For other healthcare professionals, this will give you a data-driven overview of the activity in digital health because it’s kind of important these days. 


We have the data, we want your opinions! This is only the beginning of much more to come. If you work in the pharmaceutical industry, and would like to provide us with your feedback or participate in our post-report survey, give us a shout! 

Are you a HealthXL Member? See the Full Report Here

Non- HealthXL Member? you can purchase the report HERE

Authors: Chandana Fitzgerald, Hanna Phelan, Sophie Madden and Tess Huss


We can provide an introduction on your behalf so that you can contact them directly with any questions/queries on this topic. Simply click on the link below to request an introduction.

We can provide an introduction on your behalf so that you can contact them directly with any questions/queries on this topic. Simply click on the link below to request an introduction.

Request an Introduction

We can provide an introduction on your behalf so that you can contact them directly with any questions/queries on this topic. Simply click on the link below to request an introduction.

Request an Introduction

Ready to read more? HealthXL members can access the full peak of the report on the HealthXL Community Hub.

Not yet a member of HealthXL? Download your 11 page snapshot of the report.

Download your 11 page snapshot

Connect with peers and share insights

Don't miss out on the discussion of the latest insights and reports on digital health. Meet with peers and take a deep dive for 75 minutes. Unlike at webinars, you can freely exchange experiences and insights to solve challenges and design the future of DTx.

Digital Therapeutics (DTx)
Digital Therapeutics (DTx)
Digital Therapeutics (DTx)
Digital Therapeutics (DTx)

Best routes to market for DTx in the EU

18th October @ 10:45AM EDT

Join us as we discuss the best routes to market for DTx in the EU. These 75 minute sessions are guaranteed to be filled with interesting debate and valuable insights, apply now to secure your place.

Featuring
Giuseppe Recchia
Giuseppe Recchia
Co-Founder & CEO, daVinci Digital Therapeutics
Nemanja Kovačev
Nemanja Kovačev
Digital Health Lead, Syrmia
Featuring
Giuseppe Recchia
Giuseppe Recchia
Co-Founder & CEO, daVinci Digital Therapeutics
Nemanja Kovačev
Nemanja Kovačev
Digital Health Lead, Syrmia
Digital Therapeutics (DTx)
Digital Therapeutics (DTx)
Digital Therapeutics (DTx)
Digital Therapeutics (DTx)

Companion DTx: clinical & economic evidence

20th October @ 10:45AM EDT

Join our Digital Health Meeting focused on Companion DTx: clinical and economic evidence. This informal conversation brings a variety of stakeholders together to discuss and share their thoughts and experiences around this topic.

Featuring
Jordan Silberman, MD, PhD
Jordan Silberman, MD, PhD
Director of Clinical Analytics and Research, Digital Care Delivery, Anthem, Inc.
Céline Ulmann
Céline Ulmann
Head of R&D Digital, Almirall
Featuring
Jordan Silberman, MD, PhD
Jordan Silberman, MD, PhD
Director of Clinical Analytics and Research, Digital Care Delivery, Anthem, Inc.
Céline Ulmann
Céline Ulmann
Head of R&D Digital, Almirall
Digital Therapeutics (DTx)
Digital Therapeutics (DTx)
Digital Therapeutics (DTx)
Digital Therapeutics (DTx)

DTx last mile delivery - HCPs and patients adoption

2nd November @ 11:45AM EDT

Join us in this informal conversation where we will discuss the main challenges around HCP and Patient adoption of DTx. Apply now to connect with peers and learn from fellow thought leaders in this space.

Featuring
Shrawan Patel
Shrawan Patel
Founder & MD, Strategy Health
Céline Ulmann
Céline Ulmann
Head of R&D Digital, Almirall
Featuring
Shrawan Patel
Shrawan Patel
Founder & MD, Strategy Health
Céline Ulmann
Céline Ulmann
Head of R&D Digital, Almirall
Digital Therapeutics (DTx)
Digital Therapeutics (DTx)
Digital Therapeutics (DTx)
Digital Therapeutics (DTx)

Tech Giants, Start-ups or Incumbents, who will disrupt healthcare?

4th November @ 11:30AM EDT

Join our Digital Health Meeting as discuss How do we define disruption in the healthcare industry? What is the ‘extinction event’ healthcare needs and why has it not happened yet? And what are the learnings from Tech Giants’ moves in healthcareApply now to join the conversation and share your thoughts on the topic.

Featuring
Amanda Goltz
Amanda Goltz
Principal, Business Development, Alexa Health & Wellness at Amazon
Conor Hayes
Conor Hayes
Healthcare Lead, Techvie Software
Featuring
Amanda Goltz
Amanda Goltz
Principal, Business Development, Alexa Health & Wellness at Amazon
Conor Hayes
Conor Hayes
Healthcare Lead, Techvie Software

Are you a HealthXL Member? See the Full Report Here

Non-HealthXL Member? You can purchase the report HERE

HealthXL Digital Health Meetings

Want to join the discussion now?

Join our Digital Health Meetings and take a deep dive for 75 minutes into topics like digital therapeutics, patient support, telehealth, clinical trials, dermatology and many more. These Meetings are not regular webinars: No audience, no recording and no hiding behind a screen. You actively participate in a discussion to solve your present challenges and design the future of digital health. And with a free account on our Community Hub, you stay connected and up-to-date on the latest news and insights, allowing you to fully immerse yourself in the topic before, during and after.

Digital Therapeutics (DTx)
Digital Therapeutics (DTx)
Digital Therapeutics (DTx)
Digital Therapeutics (DTx)

Best routes to market for DTx in the EU

18th October @ 10:45AM EDT

Join us as we discuss the best routes to market for DTx in the EU. These 75 minute sessions are guaranteed to be filled with interesting debate and valuable insights, apply now to secure your place.

Featuring
Giuseppe Recchia
Giuseppe Recchia
Co-Founder & CEO, daVinci Digital Therapeutics
Nemanja Kovačev
Nemanja Kovačev
Digital Health Lead, Syrmia
Featuring
Giuseppe Recchia
Giuseppe Recchia
Co-Founder & CEO, daVinci Digital Therapeutics
Nemanja Kovačev
Nemanja Kovačev
Digital Health Lead, Syrmia
Digital Therapeutics (DTx)
Digital Therapeutics (DTx)
Digital Therapeutics (DTx)
Digital Therapeutics (DTx)

Companion DTx: clinical & economic evidence

20th October @ 10:45AM EDT

Join our Digital Health Meeting focused on Companion DTx: clinical and economic evidence. This informal conversation brings a variety of stakeholders together to discuss and share their thoughts and experiences around this topic.

Featuring
Jordan Silberman, MD, PhD
Jordan Silberman, MD, PhD
Director of Clinical Analytics and Research, Digital Care Delivery, Anthem, Inc.
Céline Ulmann
Céline Ulmann
Head of R&D Digital, Almirall
Featuring
Jordan Silberman, MD, PhD
Jordan Silberman, MD, PhD
Director of Clinical Analytics and Research, Digital Care Delivery, Anthem, Inc.
Céline Ulmann
Céline Ulmann
Head of R&D Digital, Almirall
AI in Healthcare
AI in Healthcare
AI in Healthcare
AI in Healthcare

Masterclass: AI-based diagnostics - learnings from a real-world use case

21st October @ 9:00AM GMT

In this masterclass, Zachary Tan (Advisor at CancerAid; Venture Creation Partner at Aegis Ventures; more info here) & Lisa Zhu (Research Fellow of the Center for Eye Research Australia) will walk us through the key learnings from their latest article in Scientific Reports (Nature) on real-world AI-based screening for diabetic retinopathy in Australia. This early-stage study is one of the first globally to describe the real-world implementation of AI in healthcare.

Featuring
Zachary Tan
Zachary Tan
Venture Creation Partner, Aegis Ventures
Lisa Zhu
Lisa Zhu
Research Fellow, CERA
Featuring
Zachary Tan
Zachary Tan
Venture Creation Partner, Aegis Ventures
Lisa Zhu
Lisa Zhu
Research Fellow, CERA
Digital Mental Health & Neurology
Digital Mental Health & Neurology
Digital Mental Health & Neurology
Digital Mental Health & Neurology

Digital Health in Mental Health: Commercialization Models

21st October @ 10:45AM EDT

Join us in this informal conversation where we will discuss the best commercialisation models for digital companies in the mental health space. Our 75 minute sessions are guaranteed to be filled with interesting debate and great conversation.

Featuring
Robert Garber
Robert Garber
Partner, 7Wire Ventures
Sarah Fisher
Sarah Fisher
Senior Director, Global Markets, External Innovation, Johnson & Johnson Medical Devices
Featuring
Robert Garber
Robert Garber
Partner, 7Wire Ventures
Sarah Fisher
Sarah Fisher
Senior Director, Global Markets, External Innovation, Johnson & Johnson Medical Devices

What’s a Rich Text element?

The rich text element allows you to create and format headings, paragraphs, blockquotes, images, and video all in one place instead of having to add and format them individually. Just double-click and easily create content.

Static and dynamic content editing

A rich text element can be used with static or dynamic content. For static content, just drop it into any page and begin editing. For dynamic content, add a rich text field to any collection and then connect a rich text element to that field in the settings panel. Voila!

How to customize formatting for each rich text

Headings, paragraphs, blockquotes, figures, images, and figure captions can all be styled after a class is added to the rich text element using the "When inside of" nested selector system.

We cannot guarantee that the content will display correctly while using Internet Explorer. To have the best browsing experience, please upgrade to Microsoft Edge, Google Chrome or Safari.